Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

(2022) Eddy Pérez-Then et al.   NATURE MEDICINE

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

(2022) Xin Zhao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study

(2022) Jingwen Ai et al.   Emerging Microbes & Infections

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults

(2022) Yuntao Zhang et al.   Frontiers of Medicine

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

(2022) Timothy A. Bates et al.   Science Immunology

COVID-19 vaccine trials: The use of active controls and non-inferiority studies

(2021) Thomas R Fleming et al.   Clinical Trials

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2

(2021) Shiyu Sun et al.   CELL RESEARCH

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

(2021) Annabel A Powell et al.   Eurosurveillance

To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination

(2021) Nan-Chang Chiu et al.   Expert Review of Vaccines

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

(2021) Johan Normark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hybrid immunity

(2021) Shane Crotty   SCIENCE

A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia

(2021) Eddy Fadlyana et al.   VACCINE

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

(2021) Markus Hoffmann et al.   CELL

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

Waning Immunity after the BNT162b2 Vaccine in Israel

(2021) Yair Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 vaccine breakthrough infections

(2021) Ravindra K. Gupta et al.   SCIENCE

SARS-CoV-2 vaccine boosters: The time to act is now

(2021) Maya Petersen et al.   PLOS MEDICINE

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

(2021) Jingwen Ai et al.   Emerging Microbes & Infections

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants

(2021) Rüdiger Groß et al.   EBioMedicine

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Immunosenescence and human vaccine immune responses

(2019) Stephen N. Crooke et al.   Immunity & Ageing

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE